Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice
This is the treatment algorithm we have used during our discussion with @NiuSanford and @MadhuEluri for #RectalCancer
- In PROSPECT study, selectively XRT was avoided.
- In AZUR-01, selectively surgery (and Chemo) was avoided.
#OncTwitter#gism@OncUpdates
Based off VOLGA, Durva (PeriOp) + EV (3 cycles NeoAdj) is now @FDA ✅ in cis-ineligible/refusing MIBC:
- Durva + EV: 2yr EFS 64% vs 45% (HR 0.51)
- 2yr OS 78% vs 69% (HR 0.58)
- pCR 45% vs 10%
#BladderCancer#OncTwitter#gusm@OncUpdates@tompowles1